最新临床试验：硼替佐米或卡菲佐米联合来那度胺和地塞米松治疗新诊断的多发性骨髓瘤

这个随机III期临床试验，是研究硼替佐米、来那度胺和地塞米松联合应用，以观察它们在治疗新诊断多发性骨髓瘤患者中对比卡非佐米、来那度胺和地塞米松联用的效果如何。硼替佐米和卡非佐米可能通过阻断细胞生长所需的一些酶来阻止癌细胞的生长。来那度胺可帮助免疫系统杀死异常的血细胞或癌细胞。用于化疗的药物，如地塞米松，通过杀死细胞、阻止细胞分裂或阻止癌细胞扩散，以不同的方式阻止癌细胞生长。硼替佐米、来那度胺和地塞米松联用在治疗多发性骨髓瘤中是否比卡非佐米、来那度胺和地塞米松联用更有效，尚不清楚。

This randomized phase III trial studies bortezomib, lenalidomide, and dexamethasone to see how well they work compared to carfilzomib, lenalidomide, and dexamethasone in treating patients with newly diagnosed multiple myeloma. Bortezomib and carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Lenalidomide may help the immune system kill abnormal blood cells or cancer cells. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether bortezomib, lenalidomide, and dexamethasone are more or less effective than carfilzomib, lenalidomide, and dexamethasone in treating patients with multiple myeloma.